Multicentric validation of novel radiopharmaceuticals improves bladder cancer staging and therapy monitoring.
[¹⁸F]FDG remains the reference PET agent in BC; however, novel agents show encouraging results for improving staging and therapy monitoring. Broader clinical implementation requires multicentric validation and standardized imaging protocols.
No takes yet. Share an insight, caveat, or question.
Guglielmo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: